A股異動 | 豬肉股集體上漲 温氏股份漲近3%
格隆匯2月21日丨順鑫農業漲6%,京基智農漲4%,温氏股份、賽為智能、禾豐股份、天康生物漲2%,牧原股份、雙匯發展、巨星農牧漲1%。個股面上,温氏股份2022年實現營業總收入為837.39億元,同比上升28.9%;歸屬於上市公司股東的淨利潤為52.2億元,上年同期虧損134億元;公司生豬銷售量及價格同比上升,同時生產成績提高,養殖綜合成本下降,公司生豬養殖業務利潤同比大幅上升,實現扭虧為盈。此外,據2月17日消息,為推動生豬價格儘快迴歸至合理區間,發展改革委會同有關方面開展年內第一批中央凍豬肉儲備收儲工作,擬於近日收儲2萬噸凍豬肉,並指導各地同步開展地方政府豬肉儲備收儲。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.